MRI引导聚焦超声消融治疗局限性中危前列腺癌:II期试验早期结果
前瞻性II期试验纳入44例MRI可见单灶临床显著中危前列腺癌患者,行经直肠MRI引导聚焦超声局灶消融,5个月活检显示41/44(93%;95%CI:82,98)治疗区无临床显著前列腺癌,无重大治疗相关不良事件,IIEF-15与IPSS评分基线至5个月无显著差异。
要点
- 44例中41例(93%)在5个月靶向活检时治疗区无临床显著前列腺癌。
- 无重大治疗相关不良事件,IIEF-15与IPSS评分5个月时与基线无显著差异。
- 消融体积≥15 cm³者6周时IIEF-15评分下降(校正P<.01),5个月时差异未达统计学显著(校正P=.07)。
关键影像表现/征象
- 治疗结束时测量无灌注体积以评估消融范围。
- 消融体积≥15 cm³者较<15 cm³者6周时IIEF-15评分下降(校正P<.01),5个月时差异未达统计学显著(校正P=.07)。
诊断标准与关键数值
- 主要终点为5个月活检(末次记录于2019年12月),临床显著前列腺癌定义为≥6 mm的GG 1病变或任何体积的≥GG 2病变。
- 5个月活检(中位7针)示41/44例(93%;95%CI:82,98)治疗区无临床显著前列腺癌。
- IIEF-15评分基线61(IQR 34-67)与5个月53(IQR 24-65.5)比较P=.18;IPSS评分基线3.5(IQR 1.8-7)与5个月6(IQR 2-7.3)比较P=.43。
临床应用与阅片要点
- 治疗在MRI引导下经直肠进行,以MR热成像实时监控消融过程。
- 治疗结束时测量无灌注体积,可作为消融范围的影像评估指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background To reduce adverse effects of whole-gland therapy, participants with localized clinically significant prostate cancer can undergo MRI-guided focal therapy. Purpose To explore safety and early oncologic and functional outcomes of targeted focal high-intensity focused ultrasound performed under MRI-guided focused ultrasound for intermediate-risk clinically significant prostate cancer. Materials and Methods In this prospective phase II trial, between February 2016 and July 2019, men with unifocal clinically significant prostate cancer visible at MRI were treated with transrectal MRI-guided focused ultrasound. The primary end point was the 5-month biopsy (last recorded in December 2019) with continuation to the 24-month follow-up projected to December 2021. Real-time ablation monitoring was performed with MR thermography. Nonperfused volume was measured at treatment completion. Periprocedural complications were recorded. Follow-up included International Prostate Symptom Score (IPSS) and International Index of Erectile Function-15 (IIEF-15) score at 6 weeks and 5 months, and multiparametric MRI and targeted biopsy of the treated area at 5 months. The generalized estimating equation model was used for statistical analysis, and the Holm method was used to adjust P value. Results Treatment was successfully completed in all 44 men, 36 with grade group (GG) 2 and eight with GG 3 disease (median age, 67 years; interquartile range [IQR], 62-70 years). No major treatment-related adverse events occurred. Forty-one of 44 participants (93%; 95% CI: 82, 98) were free of clinically significant prostate cancer (≥6 mm GG 1 disease or any volume ≥GG 2 disease) at the treatment site at 5-month biopsy (median, seven cores). Median IIEF-15 and IPSS scores were similar at baseline and at 5 months (IIEF-15 score at baseline, 61 [IQR, 34-67] and at 5 months, 53 [IQR, 24-65.5], P = .18; IPSS score at baseline, 3.5 [IQR, 1.8-7] and at 5 months, 6 [IQR, 2-7.3], P = .43). Larger ablations (≥15 cm3) compared with smaller ones were associated with a decline in IIEF-15 scores at 6 weeks (adjusted P < .01) and at 5 months (adjusted P = .07). Conclusion Targeted focal therapy of intermediate-risk prostate cancer performed with MRI-guided focused ultrasound ablation was safe and had encouraging early oncologic and functional outcomes. © RSNA, 2021 Online supplemental material is available for this article See also the editorial by Tempany-Afdhal in this issue.
引用
- Ghai S, Finelli A, Corr K, et al. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. Radiology. 2021. PMID: 33529137. doi:10.1148/radiol.2021202717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。